Souhaitez-vous accéder aux communiqués récents ?

ALK (ALKB:DC / OMX: ALK B / AKBLF) offentliggør delårsrapport for første halvår (Q2) af 2024 om morgenen fredag den 23. august 2024. ALK afholder senere samme dag kl. 13.30 (CEST) en præsentation...

ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its results for the first six months (Q2) 2024 in the morning of 23 August 2024. Later same day, the company will host a presentation for investors...

ALK (ALKB:DC / OMX: ALK B / AKBLF) har i dag annonceret, at forventningerne til helåret er blevet opjusteret som følge af bedre end forventet salgsudvikling i andet kvartal og forbedrede udsigter for...

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook has been upgraded to reflect better than expected sales performance in Q2 and an improved outlook for the...

ALK (ALKB:DC / OMX: ALK B / AKBLF) har i dag annonceret, at selskabet har besluttet at trække sin registreringsansøgning for tabletten mod husstøvmideallergi. ALK vil fortsat samarbejde med...

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that it has decided to withdraw the Biologic License Application (‘BLA’) for its house dust mite (‘HDM’) sublingual allergy immunotherapy tablet in...

ALK (ALKB:DC / OMX: ALK B / AKBLF) har i dag meddelt, at bestyrelsen har vedtaget en ny selskabsstrategi (Allergy+) og finansielle ambitioner for 2028. Målet med Allergy+ er at udbygge ALK’s...

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the Board of Directors has adopted a new corporate strategy (Allergy+) and 2028 financial ambitions. Allergy+ aims to further strengthen...

At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took part in Valencia in Spain from 31 May to 3 June 2024, the Danish pharmaceutical company ALK...

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the European regulatory filing for ITULAZAX® (tree sublingual allergy immunotherapy (SLIT) tablet) in young children has been accepted for...